In light of the current national shortage of novel weight loss medications such as glucagon-like peptide-1 receptor agonists, fair and ethical allocation of those scarce medical resources should occur.45 The pediatric population with extremely severe obesity should be the preferred recipients of those medications (if lifestyle modifications do not lead to sufficient weight loss), as the medical intervention in this population would maximize benefits with lives, years of life, and healthy years of life saved compared with other populations. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.